Birk Venture
VC Fund
Oslo, Norway
Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Birk Venture invests in
BiotechnologyMedicalHealth CarePharmaceuticalFinance
Stages Birk Venture invests in
SeedSeries AFunding Round
Countries Birk Venture invests in
NorwayUnited Kingdom
Round sizes
Seed $1.3M–$15MSeries A $1.2M–$20M
Round size
- Seed
- $1.3M–$15M
- Series A
- $1.2M–$20M
Investment Focus
Industry
- Biotechnology 7 (78%)
- Medical 4 (44%)
- Health Care 3 (33%)
- Pharmaceutical 3 (33%)
- Finance 1 (11%)
Stage
- Seed 5 (56%)
- Series A 2 (22%)
- Funding Round 1 (11%)
Country
- Norway 6 (67%)
- United Kingdom 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Accession Therapeutics
|
Accession Therapeutics is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumor diversity. It is the first company to have engineered a viral point of entry to cancer cells while bypassing healthy cells - so it’s ‘gloves off’ in the fight against cancer." It was founded in 2020 and is locatedin Oxford, Oxfordshire, United Kingdom. | $19.6M / Series A / Nov 21, 2022 | |
|
Accession Therapeutics
|
Accession Therapeutics is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumor diversity. It is the first company to have engineered a viral point of entry to cancer cells while bypassing healthy cells - so it’s ‘gloves off’ in the fight against cancer." It was founded in 2020 and is locatedin Oxford, Oxfordshire, United Kingdom. | $15M / Seed / Sep 20, 2021 | |
Zelluna Immunotherapy
|
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies.Our goal is to revolutionize cancer therapy by developing TCR based therapies with the potential to treat a wide range of cancer types and patients.Zelluna’s core asset is a wide range of TCRsisolated from patients who exhibited long-term survival following inclusion in peptide based cancer vaccine trials initiated by Prof Gustav Gaudernack and conducted by investigators at the Norwegian Radium Hospital/Oslo University Hospital. Currently the company has several TCRs in different stages of development.We are a member of Oslo Cancer Cluster (Norwegian Centre of Expertise), a member organization for Norwegian and International stakeholders within cancer research and development. Oslo Cancer Cluster has members from the biotechnology industry, the government, patient organizations, research institutions and hospitals.Zelluna is located at the Oslo Cancer Cluster Innovation Park, next to the Norwegian Radium Hospital/Oslo University Hospital, the Department for Cellular Therapy and one of Europe’s largest academic certified GMP facilities for cellular products. | Seed / Jan 01, 2017 | |
APIM Therapeutics
|
APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress. | Oct 17, 2012 | |
Circio
|
Targovax AS develops active immunotherapy in the form of cancer vaccines. The lead candidate TG01 is currently in a phase I/II clinical trial in resectable pancreatic cancer. Patients are treated after operation, and the immune system is triggered to recognize cancer specific RAS mutations and kill the cancer cells. TG01 consists of peptidesdesigned to trigger both a helper- and cytotoxic T-cell response in the patients, ensuring a broad and lasting immune response. The Targovax peptides are designed for induction of RAS mutation specific T-helper cells through presentation on HLA class II molecules on the surface of Antigen Presenting Cells (APCs), but also for natural processing to potential HLA class I epitopes and induction of RAS mutation specific cytotoxic T cells.The T helper (Th) cells have a central and critical role in coordination of immune reactions and are often referred to as the "generals" and "conductors" of the immune system. The drug candidate has a strong historical background including clinical data. The clinical data indicate both an increase of mean survival and long-term survivors. The drug is well tolerated with a low degree of side effects. Inventors of the technology and the Radium Hospital Research Foundation established Targovax in 2010. | $1.2M / Series A / Feb 01, 2012 | |
|
APIM Therapeutics
|
APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress. | Nov 10, 2011 | |
BerGenBio
|
BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $1.3M / Seed / Mar 02, 2011 | |
Thor Medical
|
Thor Medical ASA is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics.The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs),designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities.Betalutin® is a tumour-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177). It is showing promising efficacy and tolerability in a Phase 1/2 clinical study in a difficult-to-treat NHL patient population.The company aims to develop Betalutin® for the treatment of patients with relapsed/refractory NHL.Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies.Nordic Nanovector is committed to building a pipeline of novel ARCs and antibody drug conjugates (ADCs) addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary. | Seed / Jan 01, 2010 | |
Nextera AS
|
Nexteras technology offers a highly versatile and innovative platform that finds its application in a broad array of fields leaning on protein engineering and evolution, such as life sciences, IVD, drug discovery and lead optimization.Nexteras strategy is to build on our true uniqueness and core strengths to differentiate from competition andmaximize value creation. Thus, the company focuses on high-resolution target discovery and lead candidate development in HLA class II associated mechanisms.For all leads developed by Nextera, a companion diagnostic will also be included given the nature of our applied discovery tools. | Seed / Jan 01, 2010 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FinTech Investors
43,106 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Finance Investors
15,513 investors
FinTech VC Funds
28,664 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
FAQ
What does Birk Venture invest in?
Birk Venture invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Birk Venture's check size?
Birk Venture typically joins rounds of $1.3M–$15M at Seed and $1.2M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Birk Venture participates in.
When did Birk Venture last invest?
The most recent investment recorded for Birk Venture closed in Nov 2022. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
